Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation is about finding a source for Alfatradiol 0.1% as most available products are 0.025%. A suggestion was made to use four times the dosage of the 0.025% product.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

Dr. Couto recommends taking finasteride in the morning to align with peak testosterone and DHT production for better effectiveness. Oral minoxidil is acknowledged as better than topical, but the focus is on stabilizing hair loss with finasteride first.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

A user shared their positive experience with a hair transplant performed by Dr. Timothy Carman, using 1100 grafts via FUT surgery, and reported satisfaction with the results and minimal scarring. The user continues to use minoxidil and finasteride for hair maintenance.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.

The conversation discusses using topical taurine for hair loss, with one user reporting minimal shedding but no regrowth after 10 months. Minoxidil and finasteride are mentioned as common treatments.

CB-03-01 is considered too costly and lacks a proper delivery method, making it less viable compared to RU58841, which has shown effectiveness with minimal side effects. Finasteride caused a drop in libido for one user.

The conversation is about using tretinoin with a topical finasteride/minoxidil spray for hair loss. The user seeks information on combining tretinoin with their current treatment.

The conversation discusses using Duodart (dutasteride + tamsulosin) for hair loss, with side effects like frequent urination and ejaculation issues leading to discontinuation. The user switched to German Avodart and experienced mood and erection side effects, considering adjusting the dosage to three times a week.

The user mixed tretinoin with minoxidil and noticed hair regrowth after three months, despite initial dryness. Their regimen includes 0.5mg dutasteride every other day, daily topical minoxidil with 0.025% tretinoin gel, and ketoconazole shampoo twice weekly.

The user is seeing progress in hair regrowth using a combination of 8% minoxidil, 0.25% dutasteride, and 0.01% tretinoin. The conversation includes comments on the effectiveness and application of these treatments.

A user shared a new hair loss treatment protocol including topical dutasteride, latanoprost, caffeine, minoxidil, tretinoin, and triamcinolone acetonide. Others discussed the effectiveness and availability of these treatments, with some suggesting simpler oral alternatives.

The conversation discusses experiences with Hair Stem Cell Transplantation (HST) for hair loss. Users also mention treatments like Minoxidil, finasteride, and RU58841.

A user shared their positive experience with MoriTint, a Korean scalp micro pigmentation technique that enhances the appearance of hair density without being permanent. They now offer this service in Los Angeles and emphasize its benefits for those with thinning hair, while clarifying it is not suitable for those with significant hair loss or baldness.

OP shared a 1-month progress update on using a topical solution with dutasteride, minoxidil, and tretinoin for hair loss. Users noted regrowth and discussed tretinoin's availability.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

Hair loss after telogen effluvium (TE) with thinning and possible scarring, treated with 5 mg oral minoxidil. Concerns about scarring alopecia and lack of regrowth, with suggestions to consider finasteride for better results.

A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

A user discusses using tazarotene to enhance minoxidil's effectiveness for hair regrowth, believing it will make a significant difference. Others caution about potential risks of retinoids accelerating hair loss in some individuals.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

Tretinoin alone has led to hair regrowth in the temples and hairline. The user is considering oral minoxidil or dutasteride but prioritizes health first.